Older evidence also implicates SLs in BCR-ABL independent ALL via the use of the DES1 inhibitor, N-(4-hydroxyphenyl)retinamide (fenretinide, or 4-HPR). Here, ABL1 is linked to acute lymphoblastic leukemia.